Web Exclusives

Positive findings from this study support channeling additional resources into telemedicine care for lung cancer, and into future randomized controlled trials to verify effectiveness. Read Article ›

The COVID-19 pandemic has highlighted how critical it is to maintain resilience and flexibility of the healthcare system and healthcare providers. Read Article ›

Clinical data are highlighted, providing an understanding of the benefits of treatment with tyrosine kinase inhibitors. Read Article ›

Emerging evidence suggests PARP inhibitors have the potential to revolutionize the treatment of ovarian cancer. Read Article ›

Patients with advanced ovarian cancer may be eligible to receive frontline maintenance treatment with olaparib plus bevacizumab. Read Article ›

Ovarian cancer survivors frequently use adaptive and problem-focused coping strategies. During the COVID-19 pandemic, virtual technology has played a key role in shaping and determining these strategies. Read Article ›

Oral treatments for ovarian cancer can be taken at home, in a sequestered environment that may minimize undue risks for patients. Results from a randomized phase 3 study suggest oral PARP inhibitor therapy has improved efficacy when compared with intravenous chemotherapy. Read Article ›

Telemedicine may play a critical role by creating pathways for overcoming obstacles to healthcare access, particularly for breast cancer reconstruction. Read Article ›

Patient-reported outcomes from the phase 3 PRIMA clinical trial showed no detrimental effect of niraparib on quality-of-life measures compared with placebo in patients with newly diagnosed ovarian cancer. Read Article ›

Information on clinical aspects of COVID-19 and social and financial support services for the cancer community are abundant. Read Article ›

In a systematic literature review that extracted data from 50 qualifying clinical trials, PARP inhibitor first-line maintenance improved progression-free survival (PFS) “across the board” versus other maintenance treatments in women with advanced ovarian cancer. Read Article ›

In a single-arm, single-institution study, combining pembrolizumab, bevacizumab, and metronomic oral cyclophosphamide led to a median progression-free survival of 10 months in women with recurrent ovarian cancer, with better response in women with platinum-sensitive disease. Read Article ›

Page 6 of 20